Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / JNJ - J&J to record $610M impairment charge from terminating development of therapy

JNJ - J&J to record $610M impairment charge from terminating development of therapy

Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) said that it will record a $610M impairment charge in Q1 2022 as a result of ending development of the R&D asset bermekimab for atopic dermatitis. J&J acquired the rights to bermekimab from XBiotech (NASDAQ:XBIT) in FY 2020. J&J said it is still pursuing development of bermekimab in hidradenitis suppurativa. It says it has a value of $150M in that indication. Earlier today, XBiotech said it would produce bermekimab and other products for J&J's Janssen's Research & Development unit.

For further details see:

J&J to record $610M impairment charge from terminating development of therapy
Stock Information
Company Name: Johnson & Johnson
Stock Symbol: JNJ
Market: NYSE
Website: jnj.com
Menu
JNJ JNJ Quote JNJ Short JNJ News JNJ Articles JNJ Message Board
Get JNJ Alerts

News, Short Squeeze, Breakout and More Instantly...